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Abstract
Lithium salt has been widely used in treatment of Bipolar Disorder, a mental disturbance associated with circadian rhythm
disruptions. Lithium mildly but consistently lengthens circadian period of behavioural rhythms in multiple organisms. To
systematically address the impacts of lithium on circadian pacemaking and the underlying mechanisms, we measured
locomotor activity in mice in vivo following chronic lithium treatment, and also tracked clock protein dynamics
(PER2::Luciferase) in vitro in lithium-treated tissue slices/cells. Lithium lengthens period of both the locomotor activity
rhythms, as well as the molecular oscillations in the suprachiasmatic nucleus, lung tissues and fibroblast cells. In addition,
we also identified significantly elevated PER2::LUC expression and oscillation amplitude in both central and peripheral
pacemakers. Elevation of PER2::LUC by lithium was not associated with changes in protein stabilities of PER2, but instead
with increased transcription of Per2 gene. Although lithium and GSK3 inhibition showed opposing effects on clock period,
they acted in a similar fashion to up-regulate PER2 expression and oscillation amplitude. Collectively, our data have
identified a novel amplitude-enhancing effect of lithium on the PER2 protein rhythms in the central and peripheral circadian
clockwork, which may involve a GSK3-mediated signalling pathway. These findings may advance our understanding of the
therapeutic actions of lithium in Bipolar Disorder or other psychiatric diseases that involve circadian rhythm disruptions.
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Introduction
Bipolar Disorder (BPD), also known as manic-depressive illness,
is a mood disorder that affects 1–3% of the general population.
Accumulating evidence supports the association of the disrupted
circadian rhythms with the pathogenesis and manifestation of BPD
[1–3]. For instance, during both the manic and the depression
episodes, patients show profound disturbances in sleep cycles and
hormonal secretion rhythms. For the last 60 years, lithium has
been the mainstay treatment for BPD. Lithium lengthens the
period of behavioral circadian rhythms in rodents and humans [4],
as well as the circadian firing rate rhythms in dispersed SCN
neurons [5]. However, the impacts of lithium on the dynamics of
clock gene/protein rhythms in the SCN and peripheral tissues
have not been critically investigated.
Circadian rhythms are generated by the cell autonomous
endogenous circadian clocks. In mammals, the master circadian
clock resides in the suprachiasmatic nuclei (SCN) of the
hypothalamus. Output from the SCN synchronizes via multiple
pathways peripheral oscillators in most body organs [6–8]. Within
the pacemaker cells, operation of the circadian clock relies
critically on the transcriptional/translational feedback loops.
Circadian transcription is initiated by two bHLH-PAS domain-
containing proteins CLOCK and BMAL1, which heterodimerize
and activate in an E-box dependent manner the transcriptional
repressors PERIOD (PER) and CRYPTOCHROME (CRY).
Following a delay, PER and CRY proteins are rhythmically
translocated to the nucleus to inhibit their own and other E-box
regulated promoters. Bmal1 is rhythmically regulated by two
nuclear hormone receptors, which act as activator (RORa)o r
repressor (REV-ERBa) of transcription via common RORE
elements on the Bmal1 promoter [9,10]. Glycogen synthase kinase
3b (GSK3b)-mediated phosphorylation has been implicated in the
regulation of the stability and/or nuclear translocation of PER2,
CRY2, CLOCK, REV-ERBa and BMAL1 [11–15].
As a competitive inhibitor of magnesium, lithium directly
inhibits the ATP-magnesium-dependent catalytic activity of
GSK3b [16,17]. Lithium also indirectly inhibits GSK3b activity
through enhanced phosphorylation of GSK3b at Ser9. Inhibition
of GSK3b activity have been proposed as a key pathway
mediating the effects of lithium on the circadian clocks
[12,18,19]. However, other studies [20] have demonstrated an
opposing period shortening effect upon GSK3b suppression in
cultured mammalian cells, contrasting the period lengthening
effects of lithium. Therefore, it has become pressing to understand
whether the period lengthening is the major effect of lithium
within circadian clockwork, and if so, what pathways are involved.
To address this, we performed wheel-running of mice treated
chronically with lithium, and also monitored clock gene/protein
dynamics in real-time following acute lithium treatment in vitro.
We present the following findings, 1) Lithium treatment lengthens
circadian period of behavioural rhythms, as well as the molecular
pacemaking in the SCN and periphery. 2) Expression and
oscillation amplitude of PER2::LUC in ectopic tissue explants
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lithium. 3) Increased PER2 expression in lithium-treated cells is
associated with augmented Per2 mRNA transcription, which can
be phenocopied by a selective GSK3 inhibitor, but does not
appear to involve the activity of PI3K/AKT. Our data therefore
identified a novel effect of lithium treatment on the amplitude of
PER2 protein rhythms, which may involve GSK3-mediated
mechanisms.
Materials and Methods
Ethics statement
The mouse work described here was approved by the University
Animal Ethical Review Group and conducted under a project
licence (1986 Home Office Animal Procedures Act) granted by the
UK Home Office.
Animal maintenance and behavioral analysis
PER2::LUC mice were kindly provided by Professor J.
Takahashi (the University of Texas Southwestern Medical Center
at Dallas). In this knock-in mouse, endogenous PER2 protein is
fused in-frame with a luciferase reporter, allowing real-time
monitoring of the PER2 protein dynamics by bioluminescence
recording [21]. To compare lithium responses in cells with
different decay rate of PER2, WT and CK1e
tau mice on a
PER2::LUC background produced in this laboratory were used
[22]. Only female mice were used in these studies. All mice were
maintained at 20–22uC, on standard rodent breeder or mainte-
nance chow. For wheel-running studies, 10–14 week old wild-type
C57BL/6 mice were single-housed in cages equipped with running
wheels and ad libitum food, contained within a light-tight chamber
at constant temperature (uC) and humidity (% H2O). Mice were
entrained to a 12 hour light (1000 lux) and 12 hour dark (LD)
cycle for 7–14 days and released into constant darkness (DD) for
,28 days. From this point, lithium (10 mM) was dissolved in
drinking water, a dosage which previous reports show results in a
brain concentration of about 1 mM in mice, close to the
therapeutic blood level in man of 0.5–1 mM [4]. Saline was
supplemented to adjust osmolality and avoid hyponatremia.
Chronic lithium treatment lasted 28–35 days in DD. Running
wheel activity was recorded and analyzed using ClockLab software
as described previously [22].
Reagents and antibodies
Lithium Chloride, dexamethasone, cycloheximide (CHX), AKT
inhibitor (A6730) and collagenase IA were purchased from Sigma.
PI3K inhibitor (LY294002) was purchased from Cell Signaling.
GSK3a/b inhibitor (BIO, (29Z,39E)-6-Bromoindirubin-39-oxime)
[23,24] was purchased from Calbiochem. Lithium Chloride was
dissolved in water. A6730, LY294002 and BIO were dissolved in
DMSO. The final concentrations of DMSO used were less than
0.01% in all experiments.
Cell culture and preparation of organotypic tissue slices
Primary lung fibroblasts from WT or CK1e
tau mice (both on the
PER2::LUC background) were isolated as described previously
[22]. Lungs were removed from adult mice killed by cervical
dislocation, chopped and minced. Cells were then dissociated by
means of shaking at 37uC for 2 hours in 100 u/ml of Collagenase
IA. Rat1 cell lines with or without the stably transfected Bmal1::luc
circadian reporters were used in real-time photon counting or Q-
PCR studies [25].
SCN and Lung slices from WT PER2::LUC mice were prepared
and cultured as described before [22]. Using a vibraslice
(Integraslice 7550 MM; Campden, Loughborogh), 275 mm serial
sections of brain (containing the SCN) or lung lobes were cut in 4uC
HBSS. SCN was dissected out under a dissection microscope.
Tissue slices were plated out onto Millicell 30 mm cell culture plate
inserts (Millipore) prior to synchronization and photon counting.
Bioluminescence recording and imaging
Real-time photon counting and bioluminescence imaging were
performed using Photomultiplier tube assembly (PMT, H6240
MOD1, Hamamatsu Photonics) or a CCD camera as described
previously [25,26]. Confluent cells, SCN or lung slices in 35 mm
dishes were synchronized by 100 nM dexamethasone for 1 hour
before bioluminescence recording or imaging. Data were present-
ed as photon counts per minute. Baseline correction was
calculated using a 24-hour moving average, which removed the
first 12 hours data. For the drug treatment experiments, 24 hours
after synchronization, individual dishes with cells or tissue slices
under PMT recording were treated with various drugs or vehicle
control. The treatment agent was left continuously with the
samples thereafter while the luminescence patterns were recorded.
Period was analyzed by RAP software as described before [22,27].
Amplitude was measured as the peak-trough difference 24–48 hrs
after drug treatment, based on the baseline-corrected data.
PER2::LUC decay assay
Real-time monitoring of PER2::LUC degradation was per-
formed as described before [22]. Dexamethasone-synchronized
fibroblasts or lung slices were treated with lithium for 48 hrs,
followed by CHX (20 mg/ml). Bioluminescence data after CHX
treatment were collected and analyzed by Prism (GraphPad
Software) using one-phase exponential decay curve fitting. Half-
lives were plotted as mean6 SEM.
TAQMAN Real-time quantitative PCR
Total RNA isolated from Rat1 cells were reverse transcribed
and subjected to cDNA synthesis (TaqManH Reverse Transcrip-
tion Reagents, Applied Biosystems). The following primer pairs
and probe for rat Per2 were used (59 to 39): forward:
GCAGGCTCACTGCCAGAACT; reverse:CAAGATGATTC-
TATTCCAGAAGCATT; Probe: AGCCCCAGCAAGTGATC-
GAGGACTAAG [28]. Rat housekeeping gene rb-actin was used
as an internal control. rBeta-actin forward: CGTGAAAAGAT-
GACCCAGATCA; reverse: CACAGCCTGGATGGCTACGT;
Probe: TTTGAGACCTTCAACACCCCAGCCA. The amplifi-
cation and data collection was performed on an ABI 7300
(Applied Biosystems). Each sample was run in triplicate. The data
was analysed using the 2
2DDCT method [29].
Statistical analysis
Statistical analysis was performed based on single experiments
with several samples (biological replicates). Each experiment was
repeated at least on 3 separate occasions, all repeats gave similar
results. All data were presented as mean 6 SEM, and compared
by one way ANOVA. The only exceptions were the experiments
using the AKT and PI3K inhibitors, which were based on single
experiment without repeats.
Results
Lithium lengthens circadian period in behavioural
rhythms
Lithium is known to lengthen circadian free-running rhythms in
a variety of species, including humans and rodents. By measuring
Lithium Actions on Circadian Pacemaking
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responses of wild type C57BL/6 mice following chronic treatment
of lithium chloride in drinking water. During the vehicle treated
period, mice wheel-run in constant darkness (DD) exhibited a
periodicity of 23.7760.08 hours, in line with the reported
behavioural period length for C57BL/6 mice (Fig. 1A). Following
lithium treatment, there was a mild but significant increase in
circadian period (Fig. 1A, 24.1160.10 hours, p,0.01, n=6).
Lithium impacts on clock period and PER2::LUC
oscillation amplitude in the central and peripheral
clockwork
Lithium treatment of dispersed SCN neurons lengthens the
circadian period of firing rate rhythms in a dose-dependent
manner [5]. To address whether lithium acts on the clock protein
dynamics of the central pacemaker in vitro, we treated organotypic
slices of SCN from the PER2::LUC mice with lithium.
Administration of lithium at 2 mM led to significant lengthening
of circadian period by ,1.2 hours (p,0.01, n=6, Fig. 1B), in
agreement with the behavioural period lengthening effect.
Interestingly, we also observed an elevation of PER2::LUC
expression and increase of oscillation amplitude (2.4560.86 fold
vs. control, p,0.05, n=6, Fig. 1B).
To extend these studies to non-neural oscillators, we measured
PER2::LUC bioluminescence rhythms in ectopic lung slices. Here,
we observed clear dose-dependent period lengthening of PER2::
LUC rhythms by lithium treatment, with ,2 hour extension at
10 mM (p,0.01, n=5). Similar to the SCN, there was a
significant elevation of PER2::LUC expression, with 3.8360.74
fold induction of amplitude following 10 mM lithium treatment
(Fig. 2A–D). Further bioluminescence imaging using a CCD
camera revealed that the elevated bioluminescence originated
predominantly from the bronchioles and blood vessels (Fig. 2E),
structures within the lung where the PER2 and CLOCK proteins
are known to be predominantly expressed [30].
Cultured cells harbour self-sustained and cell-autonomous
circadian clocks that resemble the molecular oscillations in the
brain, therefore providing an amenable in vitro clock model to
perform more detailed mechanistic studies [31,32]. Similar
responses to lithium were also observed in isolated lung fibroblasts
(Fig. 3A,C). There were significant dose-dependent period
lengthening effects (0.760.22 hr and 1.160.28 hr net increase
at 10 and 20 mM, respectively, p,0.05, n=4), associated with
significantly increased amplitude of PER2::LUC oscillations
(2.7060.25 fold at 20 mM, p,0.001, n=4, Fig. S1). In contrast
to ectopic SCN tissues, there were no significant effects on either
period or amplitude of PER2::LUC oscillation in lung slices or
fibroblasts treated with lower doses (1 or 2 mM) of lithium,
indicating likely tissue differences in sensitivity to lithium.
The role of GSK3 and AKT in lithium-induced clock
changes
Inhibition of GSK3b by lithium has been proposed as the
underlying mechanism of the behavioural period-lengthening
Figure 1. Lithium lengthens period for behavioral rhythms and alters molecular oscillations in the SCN. A, Representative behavioral
rhythm and period analysis for WT C57BL/6 mice. Black arrow indicates initiation of lithium treatment (10 mM in drinking water). DD, constant
darkness. Data were expressed as mean 6 SEM; **, p,0.01, n=6. B, Representative traces of PER2::LUC bioluminescence oscillations and analysis of
period and amplitude in organotypic SCN slices recorded by PMT photon counting. Black arrow indicates time of lithium treatment. Untreated group
was used as control. Data were expressed as mean 6 SEM; **, p,0.01, n=6.
doi:10.1371/journal.pone.0033292.g001
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induced period and amplitude effects, we treated lung fibroblasts
with a potent GSK3 inhibitor, BIO ((29Z,39E)-6-Bromoindirubin-
39-oxime). In contrast to the period lengthening effect of lithium,
BIO significantly shortened circadian period in lung fibroblasts (by
0.7 hour at 2 mM, p,0.05, n=4, Fig. 3B,C). However, similar to
lithium, BIO significantly increased PER2::LUC expression and
oscillation amplitude (,2 fold amplitude change at 2 mM, Fig. S1).
To explore the potential interactions between lithium and GSK3
inhibition, fibroblast cells were treated with lithium (20 mM), in
the presence or absence of BIO (2 mM). No significant additive
effects on amplitude of PER2 expression were observed compared
to lithium treatment alone (lithium alone, 2.6760.15 fold;
combined, 2.9060.34 fold, p.0.05, n=4, Fig. 3D–F). These
findings indicate that although GSK3 inhibition cannot explain
the period lengthening effect of lithium, it may play a role in the
increase of PER2::LUC amplitude upon lithium treatment.
PI3K-mediated AKT activation has also been shown as a target
of lithium in cells [33]. To explore the potential involvement of
AKT in lithium-induced PER2::LUC expression, lung fibroblasts
were pretreated with an AKT inhibitor (A6730) at doses sufficient
to suppress its kinase activity (5 fold IC50), followed by lithium
treatment. Here, the lithium-induced PER2::LUC expression,
increase of oscillation amplitude, and extension of period persisted,
irrespective of the presence or absence of the AKT inhibitor (Fig.
S2). Similar results were also found for a PI3K inhibitor
(LY294002). Treatment of cells with LY294002 at a dose 7 fold
of IC50 revealed no significant effects on lithium-induced clock
changes (Fig. S3), thus indicating lack of involvement of the PI3K/
AKT pathway in mediating Lithium actions on circadian clocks.
To investigate how lithium impacts on the dynamics of other
clock genes, we next used Rat1 cells stably transfected with
Bmal1::luc reporter [25]. Lithium lengthened period of Bmal1::luc
transcriptional rhythms in a dose-dependent manner, but there
was no significant elevation of Bmal1-driven bioluminescence level
or oscillation amplitude (Fig. 4A, B), suggesting gene-specific
effects of lithium within the molecular pacemaker.
Lithium increases Per2 mRNA levels and does not alter
PER2 protein stability
To address the possibility that lithium-induced PER2::LUC
expression may be due to increased stability of PER2 protein, we
measured the decay rate of PER2::LUC in lung fibroblasts
following cycloheximide treatment (20 mg/ml) [22]. This revealed
no significant effect of lithium on the half-life for PER2::LUC
(1.8960.03 hours for control, 1.8560.01 hours for 20 mM
lithium, p.0.05, n=4, Fig. 5A). In cultured lung slices, a similar
analysis revealed no significant change in half-life following
10 mM lithium treatment (2.1560.12 hours for control,
2.1160.08 hours for 10 mM lithium, p.0.05, n=4). If lithium
alters PER2 stability, we would predict that cells with different
decay rate of PER2 may respond differently to lithium. To test this
Figure 2. Lithium lengthens circadian period and enhances PER2::LUC expression in lung slices. A,B, Representative PER2::LUC traces
from ectopic lung slices (A, raw data; B, baseline correction of raw data). Black arrow indicates time of lithium treatment. Untreated group was used as
control. C,D, Period and amplitude analysis. The net period changes were analyzed by normalizing to the control slices and expressed as mean 6
SEM. The amplitude changes were analyzed based on the first peak after treatment in the baseline corrected data. *, p,0.05; **, p,0.01, n=5. E,
Bright field and bioluminescence imaging of lung slices. Peak and trough of oscillations were determined based on the bioluminescent intensity of
the CCD camera recording. White arrowheads indicate bronchiole and blood vessel.
doi:10.1371/journal.pone.0033292.g002
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tau
mutant mice as a model of accelerated PER2 degradation [22]. In
common with studies of WT cells, an equivalent increase in the
amplitude of PER2::LUC oscillation was observed in CK1e
tau
mutant fibroblasts (Fig. 5B,1.7160.16 fold for WT vs.1.9560.12
fold for CK1e
tau,p .0.05, n=4), supporting our result of
unaltered PER2 protein stability by lithium.
We next tested whether lithium may directly augment
endogenous Per2 transcription, leading to elevated PER2 protein
expression. This was achieved by using quantitative RT-PCR for
Per2 mRNA in dexamethasone -synchronized Rat1 fibroblast cells.
Upon lithium treatment, there was a clear dose-dependent
increase of Per2 mRNA level (,2 fold at 20 mM, P,0.01, n=4,
Fig. 5C). Interestingly, BIO also significantly enhanced Per2
mRNA level (,1.7 fold at 2 mM, P,0.05, n=4, Fig. 5C),
consistent with our earlier observations of enhanced PER2::LUC
expression by either lithium or BIO treatment. These results
therefore suggest that lithium elicits induction of Per2 transcription,
but does not alter the degradation of PER2 protein in cells.
Discussion
Lithium salt is considered to be one of the most effective drug
treatments for long term mood stabilization in BPD patients.
However, there is also large inter-individual variability in
responses to lithium, and it can cause serious side effects. It is
therefore important to understand the pharmacological actions
and molecular targets. There is compelling evidence that BPD is
associated with disruptions in circadian rhythms [2,34,35], and
lithium has been shown to robustly lengthen behavioral circadian
period in many species [4]. Consistent with earlier reports, our
results demonstrate that lithium decelerates circadian behavioural
rhythms and molecular pacemaking in the brain and peripheral
tissues and cells. However, it is unclear whether lithium has other
effects on the molecular circadian clockwork in addition to the
altered circadian clock period.
The real-time recording of PER2::LUC rhythms in tissues/cells
allowed us to systematically evaluate the effects of lithium on the
circadian clockwork. In addition to the well-established period
Figure 3. Effects of lithium and GSK3 inhibition on PER2::LUC expression and amplitude of oscillation. A,B, Representative traces of
PER2::LUC rhythms from lung fibroblasts treated with increasing doses of lithium (A) or the GSK3 inhibitor BIO (B). Black arrow indicates time of
treatment. Untreated group was used as control for lithium; DMSO was used as control for BIO. C, Period and amplitude analysis for PER2::LUC
rhythms in lung fibroblasts following treatment with either lithium (20 mM), or BIO (2 mM). Mean 6 SEM; *, p,0.05 vs. Control; **, p,0.01 vs. Control;
***, p,0.001 vs. Control; n=4 for each group. D,E, Representative raw traces (D) and baseline corrected traces (E) of PER2::LUC rhythms from lung
fibroblasts treated with lithium alone (20 mM), or in combination with BIO(2 mM). DMSO was used as vehicle control for BIO. F, Amplitude analysis for
data in (D) and (E). **, p,0.01 vs. vehicle; ***, p,0.001 vs. vehicle; n=4 for each group.
doi:10.1371/journal.pone.0033292.g003
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the PER2 protein rhythms in both central (SCN) and peripheral
clocks (lung and lung fibroblasts) is significantly augmented by
lithium. There are at least three possible explanations. First,
lithium might act as a synchronizing/resetting factor for the
cellular clocks. This is unlikely, since lithium treatment in the Rat1
fibroblast cells did not synchronize/reset the circadian transcrip-
tional cycles for Bmal1::luc. Secondly, lithium may reduce the
degradation rate of PER2 proteins, leading to PER2::LUC
accumulation, as GSK3b-mediated phosphorylation has been
implicated in the regulation of the stability of REV-ERBa [12]
and BMAL1 [13] through proteasomal degradation. This
appeared not to be the case, as PER2 turnover, as inferred from
changes in PER2::LUC decay rate, was unaltered following
lithium treatment. Finally, lithium may regulate Per2 at transcrip-
tional or post-transcriptional level. This hypothesis is supported by
our data, and by earlier reports which showed that lithium
treatment selectively increased Per2 mRNA levels in serum-
shocked NIH 3T3 cells [19,36]. Further studies are required to
understand whether and how increased transcription of Per2 leads
to enhanced amplitude of PER2::LUC rhythms, as well as to
explore the additional post-transcriptional or post-translational
mechanisms.
Clock protein REV-ERBa has been proposed as a potential
target for GSK3b and lithium [12]. These observations in HEK
293T cells provide a potential functional explanation for the
actions of lithium on the circadian clockwork. However, our
results using a Bmal1::luc reporter cell line that has RORE
elements in the Bmal1 promoter did not show significant alteration
of Bmal1::luc bioluminescence upon lithium treatment. Consistent
with our observations, studies using Northern blot analysis over a
time course of 48 hours revealed no significant increase of
endogenous Bmal1 mRNA in NIH 3T3 cells upon lithium
treatment [19]. Use of different cell line models may account for
the discrepancies observed. Therefore, further studies are required
to elucidate the contribution of REV-ERBa to lithium-induced
clock changes in the tissue/cell models used in this study.
Our studies show that both lithium and GSK3 inhibition
enhance PER2::LUC expression. An increase in amplitude by
lithium independent of GSK3 inhibition would predict that
combined treatment of lithium and GSK3 inhibitor should have
additive effects. This hypothesis is not supported by our data, since
fibroblast cells treated with both BIO and lithium demonstrated
no further significant additive effects on amplitude of PER2
expression, indicating that inhibition of GSK3 may be the causal
mechanism for induction of PER2 protein rhythms by lithium.
The period effect, on the other hand, may involve additional
mechanisms, as also suggested by Hirota et al [20].
GSK3b and the Drosophila ortholog, SHAGGY, have been
shown to directly interact with and phosphorylate mPER2 and
dPER protein, leading to nuclear translocation [15,19]. Thus,
delayed nuclear entry upon lithium treatment has been proposed
as one potential mechanism for lithium-induced period lengthen-
ing. Within the molecular oscillator, PER2 acts as the negative
regulator which suppresses transactivation of E-box regulated
genes, including its own transcription. Therefore, it is conceivable
that inhibition of GSK3b by lithium or BIO may block nuclear
entry of PER2 proteins, hence relieving its negative repression on
Per2 transcription. This may consequently lead to the induction of
Per2 and high amplitude oscillation of PER2 proteins. Interest-
ingly, recent studies using primary skin fibroblasts isolated from
BPD patients and healthy controls failed to detect any period
differences, but demonstrated significantly reduced oscillation
amplitude of several clock genes, accompanied by reduced
phosphorylation of GSK3b (hence enhanced GSK3b activity)
[37].
One limitation of the current study is that in peripheral tissues,
the concentration of lithium we used (,10 mM for lung tissues
and ,20 mM for cells) were well above the therapeutic range of
serum levels (0.5–1 mM). Similar doses have been used in other
studies to reveal the effects of lithium on circadian clocks
[12,19,20,36]. Another limitation of this study is that we only
addressed the potential roles of GSK3 and PI3K/AKT pathways
in mediating lithium actions on the circadian clockwork. In fact,
Figure 4. Lithium lengthens period of Bmal1::luc oscillation in Rat1 cells. A,B, Representative traces of PMT recording (A) and period analysis
(B) for Bmal1::luc stable Rat1 cells treated with lithium. Mean 6 SD; *, p,0.05 vs. Control; **, p,0.01 vs. Control; n=4 for each group. Untreated
group was used as control.
doi:10.1371/journal.pone.0033292.g004
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to GSK3 and PI3K/AKT pathways explored here, there will be
other known or yet to be identified targets that also impact on the
circadian clockwork. Therefore, further investigation is warranted
to identify additional mechanisms.
Collectively, our data demonstrate increased expression and
oscillation amplitude of PER2::LUC rhythms by lithium in the
SCN and peripheral tissues/cells, associated with decelerated
behavioural and molecular pacemaking. Although the period
effect of lithium may involve additional mechanisms, GSK3
inhibition phenocopies the increased Per2 mRNA levels and
enhanced amplitude of PER2::LUC rhythms. Our findings may
shed new light on the understanding of the cellular and
molecular mechanisms underlying therapeutic actions of lithium
in Bipolar Disorder, and suggest that specific targeting of GSK3b
in particular may offer novel treatment solutions for BPD
patients.
Supporting Information
Figure S1 Amplitude effects of lithium and BIO in WT
PER2::LUC fibroblast cells. Representative traces of PMT
recording to highlight the enhanced amplitude of oscillation by
lithium (A) or BIO (B). Data were subjected to baseline correction
which removed the first 12 hours data. Black arrow indicates time
of lithium or BIO treatment.
(TIF)
Figure S2 Lithium-induced PER2::LUC expression does
not appear to involve AKT activity. Representative traces of
PER2::LUC rhythms from lung fibroblasts. Cells were first treated
with the AKT inhibitor (A6730) as indicated by the arrow. After
1 hr, cells were treated with lithium (20 mM). A, raw data; B,
baseline correction of raw data. Data are presented from a single
experiment.
(TIF)
Figure 5. Lithium does not affect decay rate of PER2::LUC, but instead increases Per2 transcription. A, Decay of PER2::LUC
bioluminescence from lung fibroblasts was monitored by PMT recording. Fibroblasts were pretreated with lithium for 48 hrs, followed by treatment
with cycloheximide (CHX, 20 mg/mL). Half-lives for PER2::LUC bioluminescence were analyzed by normalizing data to the peak level of expression
(time 0 after CHX) and the minimum after 8 hours, and plotted as mean 6 SEM. Untreated group was used as control. B, Lung fibroblasts isolated
from WT and CK1e
tau mice (on PER2::LUC background) were synchronized and subjected to PMT recording. Top panel, Raw traces; bottom panel,
baseline corrected data. Black arrow indicates time of lithium treatment. C, rPer2 mRNA level was quantified by Taqman Q-PCR in Rat1 fibroblasts
synchronized with 100 nM dexamethasone. 24 hours later, cells were treated with different doses of either lithium or BIO for 12 hrs before total RNA
collection. Data were normalized to rb-actin. To calculate a relative change the average of the 3 replicate CT values for each sample was used. Mean
6 SEM *, p,0.05; **, p,0.01; n=4 for each group. Untreated group was used as control.
doi:10.1371/journal.pone.0033292.g005
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33292Figure S3 Lithium-induced PER2::LUC expression does
not appear to involve PI3K activity. Representative traces of
PER2::LUC rhythms from lung fibroblasts. Cells were first treated
with the PI3K inhibitor (LY294002) as indicated by the arrow.
After 1 hr, cells were treated with lithium (20 mM). A, raw data;
B, baseline correction of raw data. Data are presented from a
single experiment.
(TIF)
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